ABVC BioPharma, Inc. (ABVC) |
|
0.6135 -0.037 (-5.62%)
|
03-22 11:14 |
|
Open: |
0.6134 |
Pre. Close: |
0.65 |
|
High:
|
0.665 |
Low:
|
0.6134 |
|
Volume:
|
3,402 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:13:54 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.84 One year: 0.96 |
| Support: |
Support1: 0.55 Support2: 0.45 |
| Resistance: |
Resistance1: 0.72 Resistance2: 0.82 |
| Pivot: |
0.63  |
| Moving Average: |
MA(5): 0.62 MA(20): 0.64 
MA(100): 0.72 MA(250): 1.11 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 49.7 %D(3): 38.5 |
| RSI: |
RSI(14): 50.6 |
| 52-week: |
High: 3.13 Low: 0.5 |
| Average Vol(K): |
3-Month: 869 (K) 10-Days: 44 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABVC ] has closed below upper band by 29.6%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.69 - 0.69 |
0.69 - 0.69 |
|
Low:
|
0.58 - 0.59 |
0.59 - 0.59 |
|
Close:
|
0.65 - 0.65 |
0.65 - 0.66 |
|
Company Description |
|
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. |
Headline News |
Tue, 21 Mar 2023
Allergic Rhinitis Market to Exhibit Moderate Growth Rate During the ... - Digital Journal
Mon, 20 Mar 2023
ABVC BioPharma Provides Vitargus Update On Phase II Site ... - Kalkine Media
Mon, 20 Mar 2023
ABVC BioPharma Provides Vitargus® Update on Phase II Site ... - PR Newswire
Tue, 14 Mar 2023
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare - Yahoo Finance
Mon, 13 Mar 2023
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt - Simply Wall St
Thu, 23 Feb 2023
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
33 (M) |
|
% Held by Insiders
|
1.716e+007 (%) |
|
% Held by Institutions
|
40 (%) |
|
Shares Short
|
112 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.841e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
372.8 |
|
Return on Equity (ttm)
|
-100.9 |
|
Qtrly Rev. Growth
|
343000 |
|
Gross Profit (p.s.)
|
-150.79 |
|
Sales Per Share
|
-741.48 |
|
EBITDA (p.s.)
|
922921 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
1.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
163310 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-05-07 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
